Please use this identifier to cite or link to this item:
Scopus Web of Science® Altmetric
Type: Journal article
Title: Harmonization of molecular monitoring of CML therapy in Europe
Author: Muller, M.
Cross, N.
Erben, P.
Schenk, T.
Hanfstein, B.
Ernst, T.
Hehlmann, R.
Branford, S.
Saglio, G.
Hochhaus, A.
Citation: Leukemia, 2009; 23(11):1957-1963
Publisher: Nature Publishing Group
Issue Date: 2009
ISSN: 0887-6924
Statement of
MC Muller, NCP Cross, P Erben, T Schenk, B Hanfstein, T Ernst, R Hehlmann, S Branford, G Saglio and A Hochhaus
Abstract: The high efficacy of the standard treatment of chronic myeloid leukemia (CML) with imatinib has prompted the need for accurate methods to monitor response at levels below the landmark of complete cytogenetic remission. Quantification of BCR–ABL transcripts has proven to be the most sensitive method available, and has shown prognostic impact with regard to progression-free survival. Until recently, variations in methods used to quantify BCR–ABL made it difficult to compare results between laboratories. An international program is now underway to harmonize the reporting of results according to an international scale (IS). In this review, we consider the background to the IS and the progress that has been made to date, with a particular focus on ongoing harmonization efforts in Europe. We provide recommendations for the propagation of the IS by national or regional laboratory networks.
Keywords: BCR–ABL
chronic myeloid leukemia
molecular monitoring
international scale
conversion factor
Rights: © 2009 Macmillan Publishers Limited. All rights reserved
DOI: 10.1038/leu.2009.168
Published version:
Appears in Collections:Aurora harvest
Medicine publications

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.